Dr. Reddy's Laboratories share price
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories, headquartered in Hyderabad, develops, makes and sells generic medicines, including biosimilars (close copies of biological drugs), active pharmaceutical ingredients (APIs, the drug substance in a medicine), over-the-counter products and custom pharmaceutical services.1 Its customers include wholesalers, distributors, pharmacy chains, hospitals, government institutions and other drug makers, and its major markets include the United States, India, Russia and other CIS countries (former Soviet states), China, Brazil and Europe.21
It runs 24 manufacturing facilities; they include 9 API units in India, Mexico, the United Kingdom and the United States, 8 units for oral and topical medicines, 3 sterile injectable units and 3 biologics units.3 It serves patients in 88 countries and has 27,527 employees.4
It was incorporated in 1984; its founder was Kallam Anji Reddy.5 In September 2024 it completed the purchase of Haleon's nicotine replacement therapy (NRT, products that help smokers quit) brands outside the United States.6 It holds 51% of a nutraceuticals and supplements venture with Nestlé India.7 Its shares are listed on the BSE and the NSE, and its American depositary receipts (certificates for its shares traded abroad) on the New York Stock Exchange, where it is the only Indian drug maker listed.89
Its promoter group includes the GVP Family Trust and the VSD Family Trust, which held 96,095,920 and 75,630,620 shares on 31 Mar 2026.1011 G V Prasad, the co-chairman and managing director, and K Satish Reddy, the chairman, transferred shares to these trusts.125
Dr. Reddy's Laboratories key points
Results
- In the quarter to Sep 2026, consolidated revenue was ₹8,671 crore, down 1.5% on a year earlier on lower sales of lenalidomide (a blood cancer drug); EBITDA (profit before interest, tax, depreciation and amortisation) was ₹1,783 crore, a 20.6% margin.13
- Profit after tax attributable to shareholders was ₹925 crore, a 10.7% margin; net cash surplus (cash above borrowings) was ₹2,502 crore at the end of September 2026.14
- In the year to Mar 2026, consolidated revenue grew 3.2% to ₹335,933 million and EBITDA was ₹76,595 million, a 22.8% margin; excluding one-off items, the company puts growth at 4.6% and the margin at 24.7%.1516
Market position
- It ranked 8th in the Indian pharmaceutical market in the quarter to Sep 2026 and 9th over the year to Sep 2026; its India sales grew 21.0% in the quarter, against 14.7% for the market.17
- Its annual report for the year to Mar 2026 ranks it 6th in the US generics market; its US sales excluding lenalidomide grew 12.4% in the year to Aug 2026, against 2.1% for that market.1819
Business segments
- Global Generics (₹7,793 crore in the quarter to Sep 2026). Branded and unbranded prescription medicines, including biosimilars, peptides and injectables, and consumer health products.2021
- Pharmaceutical Services and Active Ingredients (₹831 crore). APIs and intermediates, plus contract development and manufacturing (CDMO) through Aurigene Pharmaceutical Services, whose CDMO revenue passed $100 million in the 12 months to Sep 2026.202223
- Others. The cancer-drug research subsidiary Aurigene Oncology and a proprietary products business; revenue was ₹2.1 billion, 1% of sales, in the year to Mar 2026.2425
Where revenue comes from
- Global Generics revenue by region262728
Item quarter to Sep 2026 North America ₹2,489 crore Emerging Markets ₹2,059 crore India ₹1,851 crore Europe ₹1,393 crore - North America revenue fell 23% on a year earlier in the quarter to Sep 2026 on lower lenalidomide sales, while Emerging Markets grew 24% and India 17%.292728
- Branded businesses (India, Emerging Markets and NRT) made up 53% of revenue in the quarter.30
Research and development
- It spent ₹24,058 million on research and development in the year to Mar 2026 and has 2,769 R&D scientists.31
- As of Sep 2026, 77 ANDAs (applications to sell a generic medicine in the US) and 3 new drug applications awaited US FDA approval, including 47 Paragraph IV filings (which challenge a patent) and 27 filed first.32
- Its biosimilars portfolio had about 15 products as of Mar 2026, 8 of them on sale; in the quarter to Sep 2026 it won US FDA approval for a rituximab biosimilar.3334
Semaglutide
- It was the first company approved to sell generic semaglutide (a diabetes and weight-loss medicine) in India and Canada, and launched it in India on the day the market opened.35
- Some batches of its semaglutide API failed specifications; it set aside ₹240 crore for inventory and other costs in the quarter to Jun 2026 and said on 23 Oct 2026 it was on track to resolve the issue.3637
- On its earnings call of 22 Jul 2026, the company said it planned to resume semaglutide supplies by November and, if API testing ending around the third week of September went well, to supply 6 to 7 million pens between November and March.3839
What the company expects
- On its earnings call of 22 Jul 2026, the company said the goal date (target decision date) for its abatacept biosimilar, a rheumatoid arthritis drug, was mid-December 2026 and that it planned to launch on approval.4041
- In its presentation of 23 Oct 2026, the company said it had partnered with Takeda for QDENGA, India's first regulator-approved dengue vaccine, and planned to launch it in private markets in the first half of 2027.42
Litigation and regulatory matters
- In US lawsuits alleging generic drug makers fixed prices from about 2009, its US subsidiary is named for 23 drugs; the company denies wrongdoing. Its annual report of 30 Jun 2026 expected bellwether (test) trials naming the subsidiary in late 2026 or 2027.4344
- US buyers and insurers allege that its patent settlement with Celgene and BMS over Revlimid (lenalidomide) delayed generic entry; as of its annual report of 30 Jun 2026, motions to dismiss were pending and no trial date was set.45
- Between Jul and Oct 2026, the US FDA issued Form 483s (lists of inspection observations) with 2 to 4 observations each at a Srikakulam process unit and formulation plants in Bachupally, Pydibhimavaram and Visakhapatnam; the company has responded or plans to.46
- In June 2026 the US FDA issued a Form 483 with 7 observations after a pre-licence inspection of its biologics plant in Bachupally, Hyderabad; the company said it had already responded.47
Last updated
All 47 sources, each with its page
- 1. Annual report, 30 Jun 2026, page 4
- 2. Annual report, 30 Jun 2026, page 83
- 3. Annual report, 30 Jun 2026, page 53
- 4. Annual report, 30 Jun 2026, page 6
- 5. Annual report, 30 Jun 2026, page 48
- 6. Annual report, 30 Jun 2026, page 248
- 7. Annual report, 30 Jun 2026, page 248
- 8. Annual report, 30 Jun 2026, page 129
- 9. Earnings call, 22 Jul 2026, page 6
- 10. Annual report, 30 Jun 2026, page 129
- 11. Annual report, 30 Jun 2026, page 129
- 12. Annual report, 30 Jun 2026, page 114
- 13. Investor presentation, 23 Oct 2026, page 4
- 14. Investor presentation, 23 Oct 2026, page 4
- 15. Annual report, 30 Jun 2026, page 14
- 16. Annual report, 30 Jun 2026, page 5
- 17. Investor presentation, 23 Oct 2026, page 11
- 18. Annual report, 30 Jun 2026, page 52
- 19. Investor presentation, 23 Oct 2026, page 9
- 20. Investor presentation, 23 Oct 2026, page 7
- 21. Annual report, 30 Jun 2026, page 52
- 22. Annual report, 30 Jun 2026, page 52
- 23. Investor presentation, 23 Oct 2026, page 13
- 24. Annual report, 30 Jun 2026, page 52
- 25. Annual report, 30 Jun 2026, page 59
- 26. Investor presentation, 23 Oct 2026, page 7
- 27. Investor presentation, 23 Oct 2026, page 10
- 28. Investor presentation, 23 Oct 2026, page 11
- 29. Investor presentation, 23 Oct 2026, page 9
- 30. Investor presentation, 23 Oct 2026, page 7
- 31. Annual report, 30 Jun 2026, page 14
- 32. Investor presentation, 23 Oct 2026, page 9
- 33. Annual report, 30 Jun 2026, page 53
- 34. Investor presentation, 23 Oct 2026, page 5
- 35. Annual report, 30 Jun 2026, page 50
- 36. Investor presentation, 23 Oct 2026, page 4
- 37. Investor presentation, 23 Oct 2026, page 6
- 38. Earnings call, 22 Jul 2026, page 5
- 39. Earnings call, 22 Jul 2026, page 10
- 40. Earnings call, 22 Jul 2026, page 15
- 41. Earnings call, 22 Jul 2026, page 11
- 42. Investor presentation, 23 Oct 2026, page 11
- 43. Annual report, 30 Jun 2026, page 243
- 44. Annual report, 30 Jun 2026, page 244
- 45. Annual report, 30 Jun 2026, page 245
- 46. Investor presentation, 23 Oct 2026, page 6
- 47. Earnings call, 22 Jul 2026, page 6
Results
Consolidated; ₹ crore.Dr. Reddy's Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −3.5%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −51.5%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8,698 Crup 7.38%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹913 Crup 109.64%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 10.5%
Revenue by quarter
Peak revenue ₹8,828 Cr, quarter to Sep 2025; lowest ₹7,546 Cr, quarter to Mar 2026
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 | 8,698 |
| Net profit | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 | 913 |
| Net margin | 16.8% | 18.6% | 16.4% | 15.1% | 13.6% | 2.9% | 5.4% | 10.5% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹33,700 Crup 3.24%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹4,158 Crdown 27.38%
- Net margin
- 12.3%
Revenue by year
Peak revenue ₹33,700 Cr, year to Mar 2026; lowest ₹14,196 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 |
| Net profit | 1,292 | 947 | 1,950 | 2,026 | 1,952 | 2,183 | 4,507 | 5,578 | 5,725 | 4,158 |
| Net margin | 9.1% | 6.6% | 12.6% | 11.6% | 10.2% | 10.1% | 18.3% | 19.9% | 17.5% | 12.3% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Global GenericsGlobal Generics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹29,946 Crup 3.33%87.0%
- Pharmaceutical Services and Active IngredientsPharmaceutical Services and Active Ingredients, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹4,267 Crdown 2.73%12.4%
- OthersOthers, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹214 Cr0.6%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history.Dr. Reddy's Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 85% of 2,479 trading days over the last 10 years.
LowestHighest
Its median26.31Industry median27.53
Price to book
At or below today's level on 8% of 1,985 trading days since Oct 2018.
LowestHighest
Its median3.58Industry median2.88
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 23% of 2,475 trading days over the last 10 years.
LowestHighest
Its median0.66%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +10.3% | −25.7% | +47.7% | 0.6% |
| 3 years | +11.4% | −2.4% | +13.5% | 0.7% |
| 5 years | +7.5% | +16.5% | −8.3% | 0.7% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
282 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 143 of the 187 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.All 282 funds holding Dr. Reddy's Laboratories
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 7
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 18
- AddedAdded. Funds that held more shares than at the end of the month before.
- 127
- CutCut. Funds that held fewer shares than at the end of the month before.
- 60
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 68
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 Parag Parikh Flexi Cap FundPPFAS Mutual Fund | 1,44,58,054 | 1.23% | ₹1,782.7 Cr |
 SBI Nifty 50 ETFSBI Mutual Fund | 1,18,28,947 | 0.72% | ₹1,458.5 Cr |
 ICICI Prudential Value FundICICI Prudential Mutual Fund | 95,69,430 | 2.06% | ₹1,179.9 Cr |
| ICICI Prudential India Opportunities FundICICI Prudential Mutual Fund | 78,44,672 | 2.65% | ₹967.2 Cr |
| ICICI Prudential Large Cap FundICICI Prudential Mutual Fund | 63,19,449 | 1.02% | ₹779.2 Cr |
| ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 54,14,201 | 9.73% | ₹667.6 Cr |
 UTI Nifty 50 ETFUTI Mutual Fund | 40,56,687 | 0.72% | ₹500.2 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 40,49,746 | 5.45% | ₹499.3 Cr |
| Nippon India Large Cap FundNippon India Mutual Fund | 40,01,922 | 0.96% | ₹493.4 Cr |
| Nippon India ETF Nifty 50 BeESNippon India Mutual Fund | 37,97,469 | 0.72% | ₹468.2 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 31 Oct 2025.Dr. Reddy's Laboratories insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade · 6 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Dr. Reddy's Laboratories competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Dr. Reddy's Laboratories in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Divi's LaboratoriesDIVISLAB | 2,59,628 | 88.76 | 15.49 | +16.3% | +26.8% | 18.4% | 20.8% | 0.31% |
 Torrent PharmaceuticalsTORNTPHARM | 1,75,479 | 82.62 | 9.55 | +42.1% | −0.7% | 15.8% | 12.0% | 0.82% |
 Laurus LabsLAURUSLABS | 1,29,972 | 97.00 | 21.45 | +23.0% | +95.9% | 24.7% | 21.8% | 0.08% |
 Zydus LifesciencesZYDUSLIFE | 1,24,239 | 27.53 | 4.58 | +21.1% | −1.3% | 17.7% | 15.9% | 0.08% |
 CiplaCIPLA | 1,11,397 | 38.45 | 3.15 | −0.7% | −46.8% | 8.5% | 9.7% | 0.94% |
 Mankind PharmaMANKIND | 1,02,964 | 45.79 | 5.86 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 96,744 | 26.06 | 2.55 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 91,961 | 16.63 | 4.10 | +28.2% | +49.5% | 27.9% | 28.2% | 0.90% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dr. Reddy's Laboratories dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹8.00 a share, in 4 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 10 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹8.00 |
| 10 Jul 2025 | Final | ₹8.00 |
| 16 Jul 2024 | Final | ₹40.00 |
| 11 Jul 2023 | Final | ₹40.00 |
| 11 Jul 2022 | Final | ₹30.00 |
| 9 Jul 2021 | Final | ₹25.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Dr. Reddy's Laboratories announcements
Oct 2026
28 Oct · General Updates
23 Oct · General Updates
Dr. Reddy's Laboratories share price by year
Each calendar year to 2025.Dr. Reddy's Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,271.40 | −8.4% | 1,375.05 | 1,087.90 |
| 2024 | 1,388.50 | +19.7% | 1,412.49 | 1,127.08 |
| 2023 | 1,159.58 | +36.8% | 1,190.67 | 840.19 |
| 2022 | 847.51 | −13.6% | 970.63 | 743.77 |
| 2021 | 981.40 | −5.7% | 1,115.14 | 842.55 |
| 2020 | 1,041.02 | +81.1% | 1,066.67 | 524.79 |
| 2019 | 574.91 | +9.9% | 595.35 | 498.51 |
| 2018 | 523.30 | +8.4% | 544.44 | 378.61 |
| 2017 | 482.84 | −21.1% | 631.83 | 386.22 |
| 2016 | 612.08 | −1.6% | 735.33 | 551.42 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 1,343.50 | 1,352.80 | 1,336.10 | 1,345.00 | 1,343.16 | 20,20,772 | 61.4% |
| 28 Oct 2026 | 1,302.00 | 1,338.20 | 1,301.00 | 1,335.40 | 1,326.77 | 28,39,063 | 63.6% |
| 27 Oct 2026 | 1,309.00 | 1,323.70 | 1,299.40 | 1,310.00 | 1,315.98 | 22,01,002 | 47.3% |
| 26 Oct 2026 | 1,260.00 | 1,319.00 | 1,224.00 | 1,310.90 | 1,285.02 | 1,00,03,270 | 28.7% |
| 23 Oct 2026 | 1,236.20 | 1,250.60 | 1,215.60 | 1,229.50 | 1,229.84 | 15,50,206 | 51.1% |
| 22 Oct 2026 | 1,236.00 | 1,250.70 | 1,212.70 | 1,239.00 | 1,232.20 | 28,05,310 | 53.1% |
| 21 Oct 2026 | 1,245.00 | 1,252.00 | 1,232.50 | 1,244.50 | 1,241.85 | 12,23,759 | 52.2% |
| 19 Oct 2026 | 1,232.00 | 1,245.00 | 1,227.00 | 1,242.50 | 1,237.37 | 10,23,837 | 47.8% |
| 16 Oct 2026 | 1,222.00 | 1,233.00 | 1,214.10 | 1,233.00 | 1,223.95 | 12,61,028 | 52.7% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 28 Oct 2024 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- DRREDDY
- BSE code
- 500124
- ISIN
- INE089A01031
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.drreddys.com
- CIN
- L85195TG1984PLC004507
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1984
- Registered office
- 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500034, Telangana
- Share registrar
- Bigshare Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 50, Nifty 100, BSE 100, Nifty 200, BSE 200, Nifty 500